China SXT Pharmaceuticals (NASDAQ:SXTC) Shares to Reverse Split on Monday, October 26th

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) shares are going to reverse split before the market opens on Monday, October 26th. The 1-100 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 25th.

China SXT Pharmaceuticals Stock Performance

Shares of NASDAQ SXTC traded down $0.03 during mid-day trading on Thursday, hitting $0.05. The company had a trading volume of 55,565,881 shares, compared to its average volume of 6,650,193. China SXT Pharmaceuticals has a 12 month low of $0.05 and a 12 month high of $83,758.80. The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02. The firm’s 50 day simple moving average is $2.22 and its two-hundred day simple moving average is $89.02.

Analysts Set New Price Targets

Several brokerages have weighed in on SXTC. Wall Street Zen upgraded China SXT Pharmaceuticals to a “sell” rating in a research note on Saturday, August 22nd. Weiss Ratings raised shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals, Inc (NASDAQ: SXTC) is a pharmaceutical company based in Taizhou, Jiangsu Province, China. The company develops, manufactures and sells traditional Chinese medicine products, serving customers primarily in the Chinese market.

Its product portfolio includes prescription and over-the-counter traditional Chinese medicines, as well as health-related products and dietary supplements. The company’s operations encompass the preparation of herbal ingredients and the production, marketing and distribution of finished traditional Chinese medicine products.

China SXT Pharmaceuticals was established in 2005 and completed its initial public offering on the Nasdaq Capital Market in 2019.